Evoke Pharma Inc
DelistedCIK 1403708fmd_1NARF3WG4VTYJ35AAXPTRZCK6QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2025, 59 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 2 | 3 | 5 | 10 |
| Research and development | 8 | 7 | 7 | 4 | 3 | 7 | 1 | 0 | 0 | 0 |
| Selling, general and administrative | – | – | – | – | 4 | 6 | 9 | 10 | 12 | 15 |
| Total operating expenses | 12 | 11 | 11 | 8 | 7 | 13 | 10 | 10 | 13 | 15 |
| Operating income | (12) | (11) | (11) | (8) | (7) | (13) | (8) | (8) | (7) | (5) |
| Interest expense | – | – | – | – | – | 0 | 1 | 1 | 1 | 1 |
| Interest and investment income | – | – | – | – | – | – | – | – | 0 | 0 |
| Other non-operating income (expense) | (0) | (0) | (1) | 0 | 0 | (0) | (0) | (0) | (0) | (0) |
| Net income | (12) | (11) | (12) | (8) | (7) | (13) | (9) | (5) | (8) | (5) |
| Net income to common shareholders | – | – | (13) | (8) | – | – | – | – | – | – |